Public Sector Pension Investment Board Buys 2,541 Shares of Becton, Dickinson and Company $BDX

Key Points

• Public Sector Pension Investment Board increased its stake in Becton, Dickinson and Company by 7.0%, now holding 38,951 shares valued at approximately $8.92 million.
• Becton, Dickinson reported a quarterly earnings per share of $3.68, exceeding analysts' expectations, with revenues rising 10.4% year-over-year to $5.51 billion.
• The company recently announced a quarterly dividend of $1.04 per share, representing a yield of 2.1%, with a dividend payout ratio of 74.82%.

Public Sector Pension Investment Board grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 7.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 38,951 shares of the medical instruments supplier's stock after purchasing an additional 2,541 shares during the quarter. Public Sector Pension Investment Board's holdings in Becton, Dickinson and Company were worth $8,922,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the business. Tranquilli Financial Advisor LLC lifted its stake in Becton, Dickinson and Company by 8.6% in the first quarter. Tranquilli Financial Advisor LLC now owns 3,381 shares of the medical instruments supplier's stock worth $774,000 after acquiring an additional 267 shares during the period. AIA Group Ltd lifted its stake in Becton, Dickinson and Company by 187.8% in the first quarter. AIA Group Ltd now owns 4,066 shares of the medical instruments supplier's stock worth $931,000 after acquiring an additional 2,653 shares during the period. Maia Wealth LLC lifted its stake in Becton, Dickinson and Company by 8.6% in the first quarter. Maia Wealth LLC now owns 1,243 shares of the medical instruments supplier's stock worth $285,000 after acquiring an additional 98 shares during the period. Cove Private Wealth LLC lifted its stake in Becton, Dickinson and Company by 46.4% in the first quarter. Cove Private Wealth LLC now owns 2,818 shares of the medical instruments supplier's stock worth $645,000 after acquiring an additional 893 shares during the period. Finally, Linscomb Wealth Inc. lifted its position in shares of Becton, Dickinson and Company by 10.3% during the first quarter. Linscomb Wealth Inc. now owns 10,855 shares of the medical instruments supplier's stock valued at $2,486,000 after buying an additional 1,011 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on BDX shares. Raymond James Financial lowered shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research report on Friday, May 2nd. Wall Street Zen raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Stifel Nicolaus decreased their price target on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Barclays cut their price objective on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a report on Tuesday, June 3rd. Finally, Wells Fargo & Company upped their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a report on Friday, August 8th. Four investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $211.44.

Becton, Dickinson and Company Trading Up 0.7%

BDX stock traded up $1.3270 during trading on Tuesday, reaching $196.3270. The company had a trading volume of 458,656 shares, compared to its average volume of 2,657,036. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99. The company has a market cap of $56.27 billion, a P/E ratio of 35.31, a PEG ratio of 1.47 and a beta of 0.20. The business has a 50 day moving average of $178.66 and a 200 day moving average of $196.21. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. During the same quarter last year, the firm earned $3.50 earnings per share. The business's revenue for the quarter was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be given a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 annualized dividend and a dividend yield of 2.1%. Becton, Dickinson and Company's dividend payout ratio (DPR) is 74.82%.

Insider Activity at Becton, Dickinson and Company

In related news, EVP David Shan sold 1,166 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the sale, the executive vice president owned 4,575 shares of the company's stock, valued at $783,194.25. This trade represents a 20.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of the firm's stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the sale, the executive vice president directly owned 4,887 shares of the company's stock, valued at $881,077.23. This trade represents a 19.52% decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,214 shares of company stock valued at $579,206 over the last 90 days. Corporate insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.